Country: Israel
Language: English
Source: Ministry of Health
BUSULFAN
RAZ PHARMACEUTICS LTD, ISRAEL
L01AB01
CONCENTRATE FOR SOLUTION FOR INFUSION
BUSULFAN 6 MG/ML
I.V
Required
TILLOMED LABORATORIES LIMITED, UK
BUSULFAN
BUSULFAN RAZ is indicated for use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation.
2023-02-08
BUSULFAN RAZ 6 MG/ML PRESCRIBING INFORMATION 1. NAME OF THE MEDICINE BUSULFAN RAZ 6 MG/ML 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 10 mL vial of BUSULFAN RAZ 6 MG/ML contains 60 mg (6 mg/mL) of busulfan . Busulfan, the active ingredient of BUSULFAN RAZ 6 MG/ML, is a white crystalline solid that is only very slightly soluble in water, sparingly soluble in acetone and slightly soluble in ethanol . For the full list of excipients, see Section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Concentrate for Solution for infusion . Clear colorless solution. BUSULFAN RAZ 6 MG/ML is supplied as a sterile solution in 10 mL single-use clear glass vials each containing 60 mg of busulfan at a concentration of 6 mg/mL for intravenous use . Busulfan Raz 6 mg/ml (Busulfan) concentrate for solution for infusion is a potent cytotoxic drug that results in profound myelosuppression at the recommended dosage. It should be administered under the supervision of a qualified physician who is experienced in the use of cancer chemotherapeutic agents and in the management of patients with severe pancytopenia. Appropriate management of therapy and complications is only possible when adequate diagnostic and treatment facilities are readily available. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS BUSULFAN RAZ 6 MG/ML is indicated for use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation. 4.2. DOSE AND METHOD OF ADMINISTRATION BUSULFAN RAZ 6 MG/ML should be administered intravenously via a central venous catheter as a two-hour infusion every 6 hours x 4 consecutive days for a total of 16 doses. All patients should be premedicated with appropriate anti-convulsant therapy (e.g. phenytoin, benzodiazepines) to prevent seizures, as busulfan is known to cross the blood brain barrier. Antiemetics of the 5-HT3 class should be administered prior to the first dose of BUSULFAN RAZ 6 MG/ML and continued on a fixed schedule through administrat Read the complete document